Intervention

trametinib

ClinicalTrials.gov intervention label

Clinical trials8
Recruiting1
Common conditions25
Lead sponsors shown4

Clinical trials

8 shown
Dabrafenib and/or Trametinib Rollover StudyNCT03340506 · 2018-01-26
RECRUITING
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study TreatmentsNCT07468071 · 2026-06-08
ACTIVE_NOT_RECRUITING
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationNCT05358249 · 2022-10-24
ACTIVE_NOT_RECRUITING
Pediatric Long-Term Follow-up and Rollover StudyNCT03975829 · 2019-11-04
ACTIVE_NOT_RECRUITING
Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLCNCT03333343 · 2018-01-29
ACTIVE_NOT_RECRUITING
Phase 1 Combination Study of MM-151 With MM-121, MM-141, or TrametinibNCT02538627 · 2015-08-01
TERMINATED
Lapatinib Plus Trametinib in KRAS Mutant NSCLCNCT02230553 · 2014-10-07
COMPLETED
Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate CancerNCT01990196 · 2014-09-23
ACTIVE_NOT_RECRUITING

Common conditions

Colorectal Cancer3Non-Small Cell Lung Cancer2Advanced Solid Tumors Harboring the KRAS G12C Mutation1Anaplastic Astrocytoma1Anaplastic Ganglioglioma1Anaplastic Oligodendroglioma1Anaplastic Pleomorphic Xanthoastrocytoma1Angiocentric Glioma1Astrocytoma1Carcinoma, Non-Small Cell Lung1Carcinoma, Non-Small-Cell Lung1Central Neurocytoma1Cerebellar Liponeurocytoma1Chordoid Glioma of Third Ventricle1Colorectal Carcinoma1Colorectal Neoplasms1Colorectal Tumors1Desmoplastic Infantile Astrocytoma and Ganglioglioma1Diffuse Astrocytoma1Dysplastic Gangliocytoma of Cerebrellum1EGFR-mutant Non-small Cell Lung Cancer1Extraventricular Neurocytoma1Gangliocytoma1Ganglioglioma1Giant Cell Astrocytoma1

Trial status mix

ACTIVE_NOT_RECRUITING5
COMPLETED1
RECRUITING1
TERMINATED1

Phase mix

PHASE15
PHASE24
PHASE42

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.